Biofrontera Inc. reports Q1 EPS (47c) vs. ($2.88) last year

Reports Q1 revenue $8.59M vs $7.91M last year. Cash and cash equivalents were $1.8M as of March 31. Hermann Luebbert, CEO and chairman of Biofrontera Inc. (BFRI), stated, “The beginning of 2025 has been a very encouraging and rewarding period for us, as we have improved our revenues by 9%. We continue to see current customers reordering as well as new medical offices coming on board and placing their initial orders of Ameluz, illustrating the strength of our products and the success of our sales and marketing efforts. As part of our combination therapy, we also sold a good mix of the two differently-sized BF-RhodoLED lamps.”